Biomarin Pharmaceutical Inc (BMRN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

Total Revenue Chart for Biomarin Pharmaceutical Inc

Biomarin Pharmaceutical Inc (BMRN) revenue for FY2025 was USD 3.2B, a 12.9% change from FY2024. Biomarin Pharmaceutical Inc's revenue grew from USD 1.2M in 1998 to USD 3.2B in 2025 (268337.8% over 27 years). Earnings per share grew from USD 0.30 in 2008 to USD 0.75 in 2022 (151.7%). Revenue compound annual growth rate: 5-year CAGR of 11.6%, 10-year CAGR of 13.7%, 20-year CAGR of 27.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$10.88B
Implied Share Price
$56.22
Enterprise Value
$15.37B
Revenue (TTM)
$3.41B
EBITDA
$645.32M
Profit Margin
2.14%
Trailing P/E
151.95
Forward P/E
9.40
Price/Book (MRQ)
1.90
Price/Sales (TTM)
3.19
EV/EBITDA
39.85
EV/Revenue
4.51
Dividend Yield
—
Book Value
$32.66
Free Cash Flow (FY2025)
$724.96M
Free Cash Flow Yield
6.66%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.